Skip to content

Safety and Efficacy Study of BrainPort® Balance Device in Peripheral Vestibular Dysfunction.

A Controlled Clinical Study to Evaluate the Safety and Efficacy of the BrainPort® Balance Device When Used to Improve Balance in Subjects With Peripheral Vestibular Dysfunction

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00768378
Enrollment
147
Registered
2008-10-08
Start date
2008-07-31
Completion date
2010-03-31
Last updated
2012-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gait Disorders, Vestibular Diseases

Keywords

Physical Therapy (Specialty), Balance dysfunction or disorder, Vestibular, Rehabilitation

Brief summary

The purpose of this study is to assess the safety and efficacy of the BrainPort balance device in improving balance and gait as measured by clinically accepted standardized balance assessments in subjects with peripheral vestibular dysfunction.

Detailed description

Peripheral vestibular dysfunction can be caused by inner ear disorders, drug toxicity, neuritis, or a number of other causes. In the absence of a fully functional vestibular system, the brain often requires retraining to correctly utilize visual and proprioceptive cues to maintain postural stability. People with vestibular dysfunction experience multiple problems with posture control and movement, including an unsteady gait and various balance-related difficulties. These effects make it very difficult to walk in the dark or on uneven surfaces without risk of falling. They are typically referred for conventional vestibular therapy. Many patients improve with therapeutic intervention. Some patients reach a plateau and do not return to their previous level of function. The BrainPort balance device transmits head position information via electrotactile stimulation of the tongue. With training, patients learn to use the positional information to correct their balance. Participants meeting the study criteria will be randomized to the perceived stimulation or subliminal stimulation group. All participants will be given baseline assessments of postural stability, balance, and subjective well being according to standardized tests. After completing the baseline assessments, each participant will be trained in the clinic using a standard training protocol with the BrainPort balance device. Each participant will participate in 6 clinical training sessions, over a period of 3 consecutive days. Upon completion of the clinic training sessions, participants will continue with a 7½ week period of home use. During this period, the participant will train with the device for 20 minutes 2 times per day and the clinicians will contact the participants weekly. At the end of the home training period (8 weeks from the beginning of the study), all participants will again undergo the tests given at baseline. Following the data analysis, subjects that have completed the 8 week study and were originally assigned to the group with inferior results will be given the opportunity to use the device that showed superior results in the data analysis.

Interventions

DEVICETraining with the BrainPort balance device

Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.

Sponsors

Wicab
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

1. Confirmed diagnosis of peripheral vestibular dysfunction by the following (within 12 months of study enrollment): 1. Bilateral Vestibular Hypofunction (BVH)-Sinusoidal rotary chair results at least 2 SD below normal across the frequency range of 0.01 to 0.32 Hz, and at least 60 deg/s peak velocity. 2. Unilateral Vestibular Hypofunction (UVH)-Bithermal caloric test results of \> 25% unilateral weakness. 2. Minimum post 3 months diagnosis with residual balance problems. 3. Previously treated with conventional physical therapy, and discharged and/or reached a plateau. 4. Functional Ability: 1. Able to ambulate independently or with an assistive device for 20 feet. 2. Ability to stand independently for 2 minutes with no or minimal upper extremity support. 3. Dynamic Gait Index ≤ 19/24. 5. Able to read and sign the informed consent form. 6. Fluent in English. 7. Willing and able to complete all testing, training, and follow-up evaluations required by the study protocol.

Exclusion criteria

1. Current oral health problems as determined by health questionnaire and an examination of the oral cavity. 2. Any medical condition that would interfere with performance on the assessments. 3. Known neuropathies of the tongue. 4. Prior exposure to BrainPort balance device. 5. History of seizures or epilepsy. 6. If female, pregnant. Subject must deny pregnancy and agree to use appropriate birth control to prevent pregnancy for the duration of the study. 7. People with implanted electrical medical devices (i.e. pacemaker, deep brain stimulator). 8. People currently taking any vestibular suppressant medication (i.e. barbiturates, benzodiazepines, betahistines or cortisone). 9. People with a previous diagnosis of a central nervous system lesion (e.g. stroke or brain injury). 10. Current diagnosis of any of the following: 1. Bilateral areflexia (no response to ice water caloric testing bilaterally) 2. Progressive neurological disease (such as Multiple Sclerosis) 3. Cervicogenic dizziness 4. Pre-syncope/syncope episodes 5. Orthostatic hypotension 6. Mood Disorders (such as Major Depression and Bipolar Disorder) 7. Anxiety disorders 8. Hydrops / Ménière's 11. Principal Investigator, in his or her medical judgment, does not believe the subject is a good candidate for the trial.

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of the BrainPort balance device in improving balance and gait as measured by the Dynamic Gait Index (DGI) in subjects with documented peripheral vestibular dysfunctionBaseline and 8 weeks (end of study)

Secondary

MeasureTime frame
To assess the safety of electrical stimulation of the tongue during the use of the BrainPort balance device in subjects with documented peripheral vestibular dysfunction.Baseline and ongoing for the duration of the study (8 weeks).
To assess improvement in the Activities-specific Balance Confidence scale (ABC).Baseline and 8 weeks (end of study)
To assess improvement in the Dizziness Handicap Inventory (DHI).Baseline and 8 weeks (end of study)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026